Delivery of Disulfiram into Breast Cancer Cells Using Folate-receptor-targeted PLGA-PEG Nanoparticles: in Vitro and in Vivo Investigations

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2016 Apr 23

PMID 27102110

Citations 52

Authors

Hamidreza Fasehee

Rassoul Dinarvand

Ardeshir Ghavamzadeh

Mehdi Esfandyari-Manesh

Hanieh Moradian

Shahab Faghihi

Seyed Hamidollah Ghaffari

Affiliations

Soon will be listed here.

Abstract

Background: A folate-receptor-targeted poly (lactide-co-Glycolide) (PLGA)-Polyethylene glycol (PEG) nanoparticle is developed for encapsulation and delivery of disulfiram into breast cancer cells. After a comprehensive characterization of nanoparticles, cell cytotoxicity, apoptosis induction, cellular uptake and intracellular level of reactive oxygen species are analyzed. In vivo acute and chronic toxicity of nanoparticles and their efficacy on inhibition of breast cancer tumor growth is studied.

Results: The folate-receptor-targeted nanoparticles are internalized into the cells, induce reactive oxygen species formation, induce apoptosis and inhibit cell proliferation more efficiently compared to the untargeted nanoparticles. The acute and toxicity test show the maximum dose of disulfiram equivalent of nanoparticles for intra-venous injection is 6 mg/kg while show significant decrease in the breast cancer tumor growth rate.

Conclusion: It is believed that the developed formulation could be used as a potential vehicle for successful delivery of disulfiram, an old and inexpensive drug, into breast cancer cells and other solid tumors.

Citing Articles

Cuproptosis, the novel type of oxidation-induced cell death in thoracic cancers: can it enhance the success of immunotherapy?.

Zhao R, Sukocheva O, Tse E, Neganova M, Aleksandrova Y, Zheng Y Cell Commun Signal. 2024; 22(1):379.

PMID: 39068453 PMC: 11282696. DOI: 10.1186/s12964-024-01743-2.

Revitalizing Cancer Treatment: Exploring the Role of Drug Repurposing.

Malla R, Viswanathan S, Makena S, Kapoor S, Verma D, Raju A Cancers (Basel). 2024; 16(8).

PMID: 38672545 PMC: 11048531. DOI: 10.3390/cancers16081463.

LIFU/MMP-2 dual-responsive release of repurposed drug disulfiram from nanodroplets for inhibiting vasculogenic mimicry and lung metastasis in triple-negative breast cancer.

Liu Y, Tang R, Cao Y, Wu N, Qin Q, Chen Y J Nanobiotechnology. 2024; 22(1):209.

PMID: 38664830 PMC: 11046851. DOI: 10.1186/s12951-024-02492-7.

Nanotechnology Applications in Breast Cancer Immunotherapy.

Wang R, Kumar P, Reda M, Wallstrum A, Crumrine N, Ngamcherdtrakul W Small. 2023; 20(41):e2308639.

PMID: 38126905 PMC: 11493329. DOI: 10.1002/smll.202308639.

Folic acid grafted mixed polymeric micelles as a targeted delivery strategy for tamoxifen citrate in treatment of breast cancer.

Nasr M, Hashem F, Teiama M, Tantawy N, Abdelmoniem R Drug Deliv Transl Res. 2023; 14(4):945-958.

PMID: 37906415 PMC: 10927891. DOI: 10.1007/s13346-023-01443-3.

References

Cvek B, Dvorak Z . Targeting of nuclear factor-kappaB and proteasome by dithiocarbamate complexes with metals. Curr Pharm Des. 2007; 13(30):3155-67. DOI: 10.2174/138161207782110390. View

Belloc F, Dumain P, Boisseau M, Jalloustre C, Reiffers J, Bernard P . A flow cytometric method using Hoechst 33342 and propidium iodide for simultaneous cell cycle analysis and apoptosis determination in unfixed cells. Cytometry. 1994; 17(1):59-65. DOI: 10.1002/cyto.990170108. View

Lewis D, Deshmukh P, Tedstone A, Tuna F, OBrien P . On the interaction of copper(II) with disulfiram. Chem Commun (Camb). 2014; 50(87):13334-7. DOI: 10.1039/c4cc04767b. View

Lin J, Haffner M, Zhang Y, Lee B, Brennen W, Britton J . Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate. 2010; 71(4):333-43. PMC: 3043358. DOI: 10.1002/pros.21247. View

Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V . High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res. 2009; 15(19):6070-8. DOI: 10.1158/1078-0432.CCR-09-1035. View

Guo X, Xu B, Pandey S, Goessl E, Brown J, Armesilla A . Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer Lett. 2009; 290(1):104-13. DOI: 10.1016/j.canlet.2009.09.002. View

Wang W, McLeod H, Cassidy J . Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer. 2003; 104(4):504-11. DOI: 10.1002/ijc.10972. View

Liu P, Wang Z, Brown S, Kannappan V, Tawari P, Jiang W . Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo. Oncotarget. 2014; 5(17):7471-85. PMC: 4202137. DOI: 10.18632/oncotarget.2166. View

Moradian H, Fasehee H, Keshvari H, Faghihi S . Poly(ethyleneimine) functionalized carbon nanotubes as efficient nano-vector for transfecting mesenchymal stem cells. Colloids Surf B Biointerfaces. 2014; 122:115-125. DOI: 10.1016/j.colsurfb.2014.06.056. View

10.

Hassani S, Ghaffari S, Zaker F, Mirzaee R, Mardani H, Bashash D . Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest. Ann Hematol. 2013; 92(9):1207-20. DOI: 10.1007/s00277-013-1763-8. View

11.

Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F . Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine. 2011; 6:877-95. PMC: 3124394. DOI: 10.2147/IJN.S18905. View

12.

Zwicke G, Mansoori G, Jeffery C . Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 2012; 3. PMC: 3521101. DOI: 10.3402/nano.v3i0.18496. View

13.

Yip N, Fombon I, Liu P, Brown S, Kannappan V, Armesilla A . Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer. 2011; 104(10):1564-74. PMC: 3101904. DOI: 10.1038/bjc.2011.126. View

14.

Chen D, Dou Q . New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer. Expert Opin Ther Targets. 2008; 12(6):739-48. PMC: 3770296. DOI: 10.1517/14728222.12.6.739. View

15.

Duan X, Xiao J, Yin Q, Zhang Z, Yu H, Mao S . Multi-targeted inhibition of tumor growth and lung metastasis by redox-sensitive shell crosslinked micelles loading disulfiram. Nanotechnology. 2014; 25(12):125102. DOI: 10.1088/0957-4484/25/12/125102. View

16.

Acharya S, Sahoo S . PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2010; 63(3):170-83. DOI: 10.1016/j.addr.2010.10.008. View

17.

Duan X, Xiao J, Yin Q, Zhang Z, Yu H, Mao S . Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano. 2013; 7(7):5858-69. DOI: 10.1021/nn4010796. View

18.

Esmaeili F, Ghahremani M, Ostad S, Atyabi F, Seyedabadi M, Malekshahi M . Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target. 2008; 16(5):415-23. DOI: 10.1080/10611860802088630. View

19.

Conticello C, Martinetti D, Adamo L, Buccheri S, Giuffrida R, Parrinello N . Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. Int J Cancer. 2012; 131(9):2197-203. DOI: 10.1002/ijc.27482. View

20.

Bae Y, Park K . Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011; 153(3):198-205. PMC: 3272876. DOI: 10.1016/j.jconrel.2011.06.001. View